Our Director of Analytical Science, Sam Whitmarsh, and our Director of Chemical Science, Rob Crook describe CatSci's robust metal control strategies and workflows that ensure alignment with the ICHQ3D requirements and ultimately patient safety.
Org. Process Res. Dev. 2022, 26, 5, 1398–1404
Org. Process Res. Dev. 2022, 26, 5, 1458–1469
CatSci's Senior Scientist, Dr Alice Dunbabin, participated in the latest Chemistry Today panel discussion on Catalysis.
Access the recordings of our 10-year anniversary symposium now. The event was centred on the future of medicines development and featured industry-leading speakers from AstraZeneca, Bristol Myers Squibb, DeepMatter, FogPharma, Merck, Novartis, R.I, Roche, Syngenta, and more.
Find out more about micellar catalysis, including its environmental, economic and productivity benefits.
Speed and efficiency are everything in pharmaceutical synthesis – and that’s why biocatalysis is an increasingly attractive option.
CatSci was tasked with catalyst screening for an asymmetrical hydrogenation of a target.
Development of a flow scavenging protocol
Dr Alan Steven explains why environmental sustainability and “big picture thinking” should be key considerations when selecting solvents for scale-up.
The client's Phase 1 process was struggling to deliver API in low kg qualities. In particular, Intermediate B was of variable quality, and residual metals were known to negatively affect the onward chemistry.
CatSci was tasked with the development of a regioselective Buchwald-Hartwig amination for the final bond forming step of an API. The inherited conditions were not robust with respect to reaction conversion leading to stability concerns.
WO2020023438
Chem. Eur. J., 2020, 26, 1–12
Dalton Trans., 2020, 49, 8169-8178
Org. Process Res. Dev. 2020, 24, 6, 1131–1140
Our Associate Principal Scientist, Dr Vargini Thangavadivale participated in the latest Chemistry Today panel discussion on catalysis
Green Chem., 2020, 22, 513-524
A general approach to the optimisation of Buchwald-Hartwig aminations for organic chemists
Development of a DKR for the manufacture of (S)-Flurbiprofen
Why Biocatalysis?